Why the Type I IFN Axis Dominates the SLE Target Landscape
Type I interferons are the single most-addressed therapeutic target in the SLE patent and literature record, because IFN-stimulated gene (ISG) overexpression is documented in the majority of SLE patients and correlates directly with disease severity. Multiple AstraZeneca patent filings explicitly state that “type I interferons are cytokines that have been implicated in SLE pathogenesis based on the finding of increased IFN-stimulated gene expression in most patients with SLE.” The quantitative scale of this dysregulation is striking: a 21-gene IFN signature—including IFI27, RSAD2, IFI44L, IFI44, OAS1, IFIT1, ISG15, OAS3, HERC5, MX1, and IFIT3—is overexpressed 8–92-fold in SLE whole blood compared with healthy controls.
SLE is a chronic, multisystem autoimmune disease in which dysregulated type I IFN signalling, pathogenic autoantibody production by autoreactive B cells, and aberrant T cell activation interact to produce significant morbidity and mortality. The therapeutic pipeline reflects this complexity: while IFNAR1 (type I IFN receptor subunit 1) blockade represents the most commercially advanced cluster, autoantibody-producing B cells constitute a second major axis addressed by CD19-directed CAR-T cells and bispecific antibodies, and upstream innate immune drivers—plasmacytoid dendritic cells (pDCs), TLR7/8 sensors, and the IL-12/IL-23 axis—are increasingly targeted as mechanistically distinct entry points into the same pathogenic network.
A 21-gene type I IFN signature, including IFI27, RSAD2, IFI44L, OAS1, IFIT1, ISG15, and MX1, is overexpressed 8–92-fold in SLE whole blood, establishing IFNAR1 as the primary validated therapeutic target in the systemic lupus erythematosus drug pipeline as of 2025.
The Oklahoma Medical Research Foundation has characterised a multicomponent soluble mediator biomarker panel—spanning Th1 cytokines (IL-12p70, IFN-γ), Th2 cytokines (IL-4, IL-13), Th17 cytokines (IL-17A, IL-6, IL-21, IL-23), and chemokines (CXCL9/MIG, CXCL10/IP-10, CCL2/MCP-1)—as predictors of SLE disease activity events. This multi-cytokine picture underscores why single-target approaches have historically struggled and why the field is increasingly moving toward biomarker-stratified patient selection. According to WHO, autoimmune diseases collectively represent a major and growing global health burden, making the development of effective, targeted SLE therapies a public health priority.
Anifrolumab and IFNAR1 Blockade: From Phase III to Life-Cycle Management
Anifrolumab (MEDI-546), an IgG1κ monoclonal antibody of approximately 148 kDa, is the most clinically advanced and commercially significant asset in the SLE pipeline covered by this dataset. It blocks the binding of all type I IFNs to IFNAR1, inhibiting their downstream biological activity across every type I IFN subtype simultaneously. AstraZeneca AB holds the dominant patent estate in this area, with more than 15 filings retrieved spanning WO, CA, SG, US, AU, JP, CN, TW, IL, and BR jurisdictions—a multi-jurisdictional footprint that reflects a sustained and expanding IP programme rather than a single foundational filing.
IFNAR1 (type I interferon receptor subunit 1) is the cell-surface receptor through which all type I interferons—including IFN-α and IFN-β—signal. Blocking IFNAR1 with anifrolumab simultaneously inhibits all type I IFN subtypes, suppressing the overactive IFN-stimulated gene expression that drives inflammation in the majority of SLE patients.
The clinical evidence base for anifrolumab is the most robust in this dataset. The phase IIb MUSE trial enrolled 305 patients, randomised to IV anifrolumab 300 mg, 1,000 mg, or placebo every 4 weeks for 48 weeks, with stratification by SLEDAI-2000 score, oral corticosteroid (OCS) dose, and 4-gene IFN signature status. The primary endpoint was SRI(4) response at Week 24 with sustained corticosteroid reduction. The subsequent phase III TULIP-2 trial demonstrated that significantly more anifrolumab-treated patients achieved BICLA response at Week 52 versus placebo, ultimately supporting FDA approval—referenced in a 2022 critical appraisal from Walter Reed National Military Medical Center and the National Human Genome Research Institute.
“The 21-gene type I IFN signature is overexpressed 8–92-fold in SLE whole blood—a pharmacodynamic magnitude that positions IFNAR1 blockade as a mechanistically direct and measurable intervention in the disease’s primary pathogenic driver.”
Beyond the core SLE treatment indication, AstraZeneca’s IP programme signals a classic life-cycle management strategy. Filings cover flare prevention across mucocutaneous, musculoskeletal, and renal organ domains; steroid-sparing as a co-primary endpoint (recognising that OCS toxicity is an independent contributor to SLE morbidity); a subcutaneous dosing regimen to reduce healthcare system burden; and—in a 2023 IL-jurisdiction filing—inhibition of type I IFN signalling for cardiometabolic comorbidities in SLE patients, with data on NET complex normalisation, cholesterol efflux capacity (CEC) restoration, and modulation of IL-10 and TNF. This cardiometabolic extension suggests a potential indication expansion well beyond classical disease activity endpoints.
The competitive landscape for IFNAR1 blockade is contextualised by the failure of PF-04236921 (an anti-IL-6 monoclonal antibody), which is referenced across multiple AstraZeneca flare-treatment patents as a failed comparator: the primary SRI-4 endpoint was not met at 24 weeks, and a 200 mg dose arm was discontinued due to three deaths. This failure underscores the difficulty of SLE drug development and the clinical significance of the TULIP-2 BICLA data. According to EMA, robust phase III evidence with validated disease activity endpoints is essential for regulatory approval in complex autoimmune indications.
Map AstraZeneca’s full anifrolumab patent estate and identify freedom-to-operate gaps with PatSnap Eureka.
Explore the SLE Patent Landscape in PatSnap Eureka →The phase IIb MUSE trial of anifrolumab in SLE enrolled 305 patients randomised to IV anifrolumab 300 mg, 1,000 mg, or placebo every 4 weeks for 48 weeks, with the primary endpoint of SRI(4) response at Week 24 with sustained corticosteroid reduction; the subsequent phase III TULIP-2 trial demonstrated significantly more patients achieving BICLA response at Week 52 with anifrolumab versus placebo, supporting FDA approval.
CD19-Directed CAR-T and Antibody Therapies: Converging on B Cell Elimination
CD19-directed therapies represent the highest-risk, highest-potential emerging modality in the SLE pipeline, with multiple large-company filings converging on this approach within a short 2024–2025 window. The therapeutic rationale is grounded in the central role of autoreactive B cells: SLE patients carry detectable anti-dsDNA, anti-histone, anti-chromatin, and anti-Sm autoantibodies, and CD19 is validated as the primary B cell surface antigen for both adoptive cell and antibody-based depletion strategies.
CAR-T Cell Therapy
Juno Therapeutics, Inc. (Bristol-Myers Squibb) holds two 2025 IL-jurisdiction patents describing adoptive cell therapy using T cells expressing a CD19-directed chimeric antigen receptor (CAR) for SLE and other systemic autoimmune diseases. The filings specify eligibility criteria including fulfilment of the 2019 ACR/EULAR SLE classification criteria and detectable autoantibodies, with lupus nephritis explicitly noted as a target indication. A separate WO 2025 patent covers rapcabtagene autoleucel—a CD19 CAR-expressing autologous cell product—specifically for SLE treatment. Novartis AG’s WO 2024 patent on CAR therapy for autoimmune disorders specifies methods for treating severe refractory SLE (srSLE) and lupus nephritis using immune effector cells (T cells, NK cells) engineered to express a CAR, directly addressing patients who fail conventional therapies including belimumab and anifrolumab. These filings represent IP positioning rather than reported clinical results for SLE specifically.
Anti-CD19 Antibody and CD20/CD3 Bispecific
Xencor, Inc. filed a 2023 IL-jurisdiction patent describing methods of treating SLE using an anti-CD19 antibody guided by biomarker detection—integrating B cell-targeted therapy with companion diagnostics. Genentech, Inc. filed a 2023 CA-jurisdiction patent covering mosunetuzumab, an anti-CD20/anti-CD3 bispecific antibody that engages CD3+ T cells to redirect cytotoxic activity toward CD20+ B cells, enabling B cell depletion through a T cell-engaging mechanism distinct from direct anti-CD20 monotherapy. This represents a strategy repurposed from oncology, where mosunetuzumab is already established. As FDA guidance on bispecific antibodies continues to evolve, the regulatory pathway for oncology-to-autoimmunity repurposing will be an important consideration for IP and clinical teams.
Multiple large-company filings from Juno Therapeutics (BMS), Novartis, and independent WO filers converged on CD19-directed CAR-T cell therapy for severe refractory SLE within a short 2024–2025 filing window, indicating competitive patent landscape acceleration. Early IP positioning on manufacturing, dosing, and patient selection criteria will be critical for differentiation.
Juno Therapeutics, Novartis, and an independent WO filer covering rapcabtagene autoleucel all filed CD19-directed CAR-T cell therapy patents for severe refractory systemic lupus erythematosus (srSLE) and lupus nephritis between 2024 and 2025, targeting patients who fail conventional therapies including belimumab and anifrolumab.
Upstream IFN Suppression: ILT7, TLR7/8, and Emerging Modalities
ILT7 blockade and TLR7/8 antagonism address the type I IFN axis at points upstream of IFNAR1, targeting the cellular machinery that generates IFN rather than the receptor through which it signals. This mechanistic distinction is clinically relevant: patients who do not respond to or cannot tolerate IFNAR1 blockade may benefit from upstream IFN suppression, and combination approaches targeting both production and signalling are a plausible future direction.
ILT7 / pDC Depletion (VIB7734)
Viela Bio, Inc. (subsequently acquired by Horizon Therapeutics) holds patents in IL and JP jurisdictions covering VIB7734, an ILT7-binding protein that depletes plasmacytoid dendritic cells (pDCs)—the primary cellular source of type I IFNs in SLE. The retrieved filings describe a Phase Ia randomised, single ascending dose study in SLE, Sjögren’s syndrome, dermatomyositis, polymyositis, and systemic sclerosis, using circulating pDC reduction as a pharmacodynamic endpoint. Viela Bio uses IFN gene signature high/low status to select pDC-targeting therapy candidates, establishing IFNGS-based eligibility criteria as a component of the IP estate. The ILT7/pDC axis is currently covered by a relatively concentrated IP estate, positioning VIB7734 as a potential option for IFNAR1-refractory patients or as a combination partner.
TLR7/8 Small-Molecule Antagonists
Eisai R&D Management Co., Ltd. holds an ES-jurisdiction patent (2019, active) covering tetrahydropyrazolopyrimidine compounds as TLR7 and/or TLR8 antagonists for SLE and lupus nephritis. TLR7/8 activation by self-nucleic acids drives pDC and B cell-mediated type I IFN production and autoantibody generation, making small-molecule TLR7/8 blockade a mechanistically distinct, potentially oral alternative to biologic IFNAR1 inhibition. This approach targets the same type I IFN axis as anifrolumab and VIB7734 from a distinct entry point and remains at the preclinical/small-molecule chemistry stage in this dataset.
IL-12/IL-23p40 Blockade (Ustekinumab)
Janssen Biotech, Inc. holds the most prolific non-IFN patent family in this dataset, with filings across WO, US, CA, IL, AU, and JP jurisdictions covering ustekinumab (STELARA)—a fully human IgG1κ monoclonal antibody binding the shared p40 subunit of IL-12 and IL-23—for active SLE. The mechanism involves blockade of IL-12/IL-23 binding to IL-12Rβ1 on NK cells and CD4+ T cells, inhibiting Th1/Th17 pathway activation. Phase II SRI-4 and SLEDAI-2K endpoint data are referenced in filings, and the marketing approval of ustekinumab for psoriasis and Crohn’s disease is used to support a safety precedent for SLE development. According to WIPO, the Janssen ustekinumab SLE patent family spans more than 10 filings across six jurisdictions, one of the broadest single-molecule estates in this analysis.
Emerging Modalities: IL-17A/IL-36R Bispecific and Circular RNA
Shanghai Huaota Biopharmaceutical Co., Ltd. filed a JP-jurisdiction patent (2026) covering antigen-binding proteins targeting IL-17A and IL-36R—or a bispecific antibody against both—for SLE and lupus nephritis. IL-17A is noted as highly expressed in active SLE patients. This dual-cytokine blockade strategy is not previously centred in the SLE pipeline and represents emerging Chinese biopharma interest in this space. Separately, a Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences patent (JP jurisdiction, 2025) describes use of circular RNA with an imperfect duplex structure (16–33 bp) to suppress PKR phosphorylation, downregulate IFN-β, and reduce expression of SLE diagnostic genes MX-1, LY-6E, and IFIT3 in SLE patient PBMCs and immune T cells—an RNA-based, non-antibody approach to type I IFN pathway modulation at the preclinical/mechanistic stage.
Track emerging SLE targets including ILT7, TLR7/8, and IL-36R across global patent filings in real time.
Search SLE Targets in PatSnap Eureka →Biomarker Stratification as a Competitive IP Asset
Biomarker-based patient stratification is becoming an IP asset in its own right, with multiple assignees filing companion diagnostic claims alongside therapeutic method claims. This trend has significant implications for freedom-to-operate, clinical access, and competitive differentiation in the SLE space.
Janssen’s most recent (2023–2025) patent filings introduce a composite scoring approach using IFN-I inducible gene expression and cytotoxic cell-associated transcriptional gene expression profiles to identify likely ustekinumab responders. This companion diagnostic IP could function as a gatekeeping tool for clinical access to anti-IL-12/23 therapy in SLE. Similarly, Viela Bio’s ILT7 filings use IFN gene signature high/low status as an eligibility criterion for pDC-targeting therapy, establishing IFNGS-based patient selection as a protectable method. The Oklahoma Medical Research Foundation has filed three US/WO/CA patents (2021–2024) covering SLE disease activity biomarker panels—including Th1, Th2, Th17, and chemokine signatures—for predicting flares and characterising immune activity.
The 4-gene to 21-gene IFN-stimulated gene panels used across AstraZeneca, MedImmune/Brigham and Women’s, Viela Bio, Janssen, and Oklahoma Medical Research Foundation filings represent a convergent pharmacodynamic biomarker infrastructure. Genes consistently cited across assignees include IFI27, RSAD2, IFI44L, OAS1, IFIT1, ISG15, and MX1. Developers entering the anti-IL-12/23 or anti-pDC space should assess freedom to operate around these biomarker selection claims. As noted by NIH, validated biomarker panels are increasingly required for regulatory approval in precision autoimmune indications, making these IP claims strategically valuable beyond the therapeutic asset itself.
Janssen Biotech’s 2023–2025 SLE patent filings introduce composite biomarker scoring using IFN-I inducible gene expression and cytotoxic cell-associated transcriptional profiles to identify ustekinumab responders, establishing companion diagnostic IP as a protectable gatekeeping asset in the SLE pipeline.
Strategic Implications for IP and Drug Development Teams
The SLE patent and literature landscape in this dataset reveals a field at an inflection point: one modality has achieved regulatory approval, a second cluster is accelerating toward clinical proof-of-concept, and a third wave of mechanistically diverse approaches is emerging from early-stage filings. For IP and drug development teams, several strategic signals are actionable.
IFNAR1 blockade is the dominant commercial IP cluster. AstraZeneca’s multi-jurisdictional anifrolumab estate covers core SLE treatment, subcutaneous administration, steroid sparing, organ-domain-specific labelling, and cardiometabolic comorbidity—a life-cycle management strategy that IP teams should monitor for freedom-to-operate and differentiation opportunities. The cardiometabolic extension (NET complex normalisation, CEC restoration) represents a potential indication expansion beyond classical SLE disease activity endpoints.
CD19-targeted B cell elimination via CAR-T represents the highest-risk, highest-potential emerging modality. The convergence of Juno Therapeutics (BMS), Novartis, and rapcabtagene autoleucel filings within a short 2024–2025 window indicates competitive patent landscape acceleration. Early IP positioning and clinical differentiation on manufacturing, dosing, and patient selection criteria will be critical for any entrant in this space.
The ILT7/pDC axis represents a mechanistically differentiated alternative to direct IFNAR1 blockade. VIB7734’s Phase Ia signal and distinct upstream mechanism—pDC depletion rather than receptor blockade—position it as a potential option for IFNAR1-refractory patients or as a combination partner. The relatively concentrated IP estate in this area means that new entrants face a defined freedom-to-operate challenge.
TLR7/8 small-molecule inhibitors and circRNA modulators remain early-stage but represent diversification away from biologic dependency. Eisai’s TLR7/8 antagonist and the Chinese Academy circRNA approach target the same type I IFN axis as anifrolumab from distinct mechanistic entry points, offering potential for oral or nucleic acid-based SLE therapies—spaces currently underrepresented in the commercial pipeline. The PatSnap innovation intelligence platform enables teams to monitor these early-stage signals across global patent jurisdictions in real time, providing a systematic advantage in identifying white-space opportunities before they become crowded.
- AstraZeneca holds more than 15 patent filings across 8+ jurisdictions for anifrolumab in SLE—the largest single-assignee estate in this dataset.
- Janssen Biotech holds more than 10 filings across 6 jurisdictions for ustekinumab in SLE, the second most prolific estate.
- The BUTTERFLY phase II trial of PF-04236921 (anti-IL-6 mAb) failed its primary SRI-4 endpoint at 24 weeks, with a 200 mg dose arm discontinued due to three deaths—illustrating the high attrition risk in SLE drug development.
- Biomarker-guided patient selection (IFN gene signature status, composite transcriptional scoring) is being filed as protectable IP by Janssen, Viela Bio, and others—creating potential gatekeeping mechanisms for clinical access.
- Chinese biopharma (Shanghai Huaota, Chinese Academy of Sciences) is entering the SLE pipeline with novel dual-cytokine bispecific and RNA-based approaches, signalling a diversifying competitive landscape.
For drug development teams navigating this landscape, PatSnap Eureka provides AI-powered patent search and analysis across the full SLE IP estate—enabling rapid identification of assignee activity, claim scope, and white-space opportunities across all nine modalities covered in this analysis. Access the PatSnap pharmaceutical intelligence suite for deeper pipeline and IP analytics.